JPWO2019138367A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019138367A5 JPWO2019138367A5 JP2020538785A JP2020538785A JPWO2019138367A5 JP WO2019138367 A5 JPWO2019138367 A5 JP WO2019138367A5 JP 2020538785 A JP2020538785 A JP 2020538785A JP 2020538785 A JP2020538785 A JP 2020538785A JP WO2019138367 A5 JPWO2019138367 A5 JP WO2019138367A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cooh
- hydrogen
- virus
- conh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023211350A JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841001438 | 2018-01-12 | ||
| IN201841001438 | 2018-01-12 | ||
| PCT/IB2019/050219 WO2019138367A1 (en) | 2018-01-12 | 2019-01-11 | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211350A Division JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514345A JP2021514345A (ja) | 2021-06-10 |
| JPWO2019138367A5 true JPWO2019138367A5 (enExample) | 2022-01-18 |
| JP7438955B2 JP7438955B2 (ja) | 2024-02-27 |
Family
ID=67213573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538785A Active JP7438955B2 (ja) | 2018-01-12 | 2019-01-11 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
| JP2023211350A Active JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211350A Active JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11274123B2 (enExample) |
| EP (1) | EP3737401A4 (enExample) |
| JP (2) | JP7438955B2 (enExample) |
| KR (2) | KR102800305B1 (enExample) |
| CN (1) | CN111601801A (enExample) |
| AU (2) | AU2019206438B2 (enExample) |
| BR (1) | BR112020014202A2 (enExample) |
| CA (1) | CA3087841A1 (enExample) |
| CU (1) | CU24643B1 (enExample) |
| EA (1) | EA202091267A1 (enExample) |
| IL (1) | IL275952B1 (enExample) |
| MX (1) | MX2020007383A (enExample) |
| MY (1) | MY200800A (enExample) |
| PH (1) | PH12020551062A1 (enExample) |
| SG (1) | SG11202005992XA (enExample) |
| WO (1) | WO2019138367A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019206438B2 (en) * | 2018-01-12 | 2023-12-07 | Aurigene Oncology Limited | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways |
| EA202190776A1 (ru) * | 2018-11-08 | 2021-09-20 | Ориджен Дискавери Текнолоджис Лимитед | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR102690136B1 (ko) * | 2021-06-30 | 2024-07-31 | 연세대학교 산학협력단 | 바이러스 및 박테리아의 중복 감염 치료용 조성물 |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025083628A1 (en) | 2023-10-19 | 2025-04-24 | Aurigene Oncology Limited | Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025229631A2 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER |
| US20250339404A1 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| JP5369257B2 (ja) * | 2006-02-15 | 2013-12-18 | アッヴィ・インコーポレイテッド | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびそれらの糖尿病、肥満および代謝症候群での使用 |
| JP6166177B2 (ja) | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| JP6521977B2 (ja) * | 2013-09-06 | 2019-05-29 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての１，２，４−オキサジアゾール誘導体 |
| ITTO20130731A1 (it) | 2013-09-09 | 2015-03-10 | Indesit Co Spa | Muffola di un forno nella quale sono fissate delle guide |
| EA201791629A1 (ru) | 2015-03-10 | 2018-02-28 | Ауриджен Дискавери Текнолоджис Лимитед | 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов |
| SMT202200163T1 (it) * | 2015-03-10 | 2022-05-12 | Aurigene Discovery Tech Ltd | Composti di 1,2,4-0ssadiazolo e tiadiazolo come immunomodulatori |
| SG11201706902SA (en) * | 2015-03-10 | 2017-09-28 | Aurigene Discovery Tech Ltd | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| US9650441B2 (en) | 2015-09-21 | 2017-05-16 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| CA3048193A1 (en) * | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| WO2017194627A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New compounds and pharmaceutical use thereof in the treatment of cancer |
| AU2019206438B2 (en) * | 2018-01-12 | 2023-12-07 | Aurigene Oncology Limited | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways |
| EA202190776A1 (ru) * | 2018-11-08 | 2021-09-20 | Ориджен Дискавери Текнолоджис Лимитед | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами |
-
2019
- 2019-01-11 AU AU2019206438A patent/AU2019206438B2/en active Active
- 2019-01-11 IL IL275952A patent/IL275952B1/en unknown
- 2019-01-11 JP JP2020538785A patent/JP7438955B2/ja active Active
- 2019-01-11 US US16/245,860 patent/US11274123B2/en active Active
- 2019-01-11 CU CU2020000046A patent/CU24643B1/es unknown
- 2019-01-11 BR BR112020014202-6A patent/BR112020014202A2/pt unknown
- 2019-01-11 SG SG11202005992XA patent/SG11202005992XA/en unknown
- 2019-01-11 MX MX2020007383A patent/MX2020007383A/es unknown
- 2019-01-11 CA CA3087841A patent/CA3087841A1/en active Pending
- 2019-01-11 EA EA202091267A patent/EA202091267A1/ru unknown
- 2019-01-11 CN CN201980007859.6A patent/CN111601801A/zh active Pending
- 2019-01-11 KR KR1020207020398A patent/KR102800305B1/ko active Active
- 2019-01-11 EP EP19738566.9A patent/EP3737401A4/en active Pending
- 2019-01-11 KR KR1020257013071A patent/KR20250057146A/ko active Pending
- 2019-01-11 MY MYPI2020003578A patent/MY200800A/en unknown
- 2019-01-11 WO PCT/IB2019/050219 patent/WO2019138367A1/en not_active Ceased
-
2020
- 2020-07-10 PH PH12020551062A patent/PH12020551062A1/en unknown
-
2021
- 2021-01-22 US US17/155,242 patent/US11560403B2/en active Active
-
2023
- 2023-01-05 US US18/150,246 patent/US20230144653A1/en active Pending
- 2023-12-14 JP JP2023211350A patent/JP7698699B2/ja active Active
-
2024
- 2024-03-04 AU AU2024201411A patent/AU2024201411A1/en active Pending